Intrathecal Nicardipine
PreclinicalSmall molecule
Intrathecal Nicardipine is one of 28 small molecule programs targeting Subarachnoid Hemorrhage. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Subarachnoid Hemorrhage
#DrugCompanyPhaseTrials
1Cardene
Sun Pharmaceutical Industries, Inc.Approved
Keppra
UCBApproved
Olumiant
Eli LillyApproved
Pletal
OtsukaApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Duragesic
CCephalon
Approved
Marcaine
IInnocoll
Approved
Angiomax
BBaxter Healthcare Corporation
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intrathecal Nicardipine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details